Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
Moskovich D, Alfandari A, Finkelshtein Y, Weisz A, Katzav A, Kidron D, Edelstein E, Veroslavski D, Perets R, Arbib N, Kadan Y, Fishman A, Lerer B, Ellis M, Ashur-Fabian O. Moskovich D, et al. Among authors: finkelshtein y. Cancer Lett. 2021 Mar 31;501:224-233. doi: 10.1016/j.canlet.2020.11.011. Epub 2020 Nov 19. Cancer Lett. 2021. PMID: 33221455
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, Ashur-Fabian O. Moskovich D, et al. Among authors: finkelshtein y. Oncogene. 2021 Nov;40(44):6248-6257. doi: 10.1038/s41388-021-02020-z. Epub 2021 Sep 23. Oncogene. 2021. PMID: 34556811
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
Moskovich D, Alfandari A, Finkelshtein Y, Weisz A, Katzav A, Kidron D, Edelstein E, Veroslavski D, Perets R, Arbib N, Kadan Y, Fishman A, Lerer B, Ellis M, Ashur-Fabian O. Moskovich D, et al. Among authors: finkelshtein y. Cancer Lett. 2023 Jun 1;563:216196. doi: 10.1016/j.canlet.2023.216196. Epub 2023 Apr 25. Cancer Lett. 2023. PMID: 37104919 No abstract available.
Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, Ashur-Fabian O. Moskovich D, et al. Among authors: finkelshtein y. Oncogene. 2023 May;42(18):1508. doi: 10.1038/s41388-023-02629-2. Oncogene. 2023. PMID: 36922680 No abstract available.